建模阿尔茨海默病的基因型-蛋白质相互作用和相关性:一个多omics成像遗传学研究研究
Jin Zhang1, Zikang Ma1, Yan Yang1
1Department of Intelligent Science and Technology, Northwestern Polytechnical University School of Automation, 127 Youyi Road, 710072 Shaanxi, China.
Briefings in bioinformatics
|February 13, 2024
概括
这项研究介绍了MT-GPIC,这是一种新的方法,用于解开阿尔茨海默氏病 (AD) 基因组数据中的基因型-蛋白质相互作用和相关性. 它增强了对AD复杂的遗传和成像联系的理解.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 生物统计学 生物统计学
背景情况:
- 阿尔茨海默病 (AD) 研究整合了基因组学,蛋白质组学和放射学,以全面理解.
- 当前的方法往往忽略了非添加效应,如基因型-蛋白相互作用 (GPI) 和脑成像遗传学中的相关性模式.
- 这些被忽视的非添加效应可能会显著影响中间成像表型和疾病进展.
研究的目的:
- 解决尚未开发的挑战,即从脑成像遗传学中的相关性模式中解脱基因型-蛋白相互作用 (GPI).
- 引入一种新的计算方法,即多任务基因型-蛋白相互作用和相关性 (MT-GPIC),用于识别GPI并提取相关性模式.
- 通过使用新的处罚和考虑大脑区域相互连接来提高发现的解释性和稳定性.
主要方法:
- 开发MT-GPIC方法,同时识别基因型-蛋白相互作用和相关性模式.
- 对于识别有意义的遗传风险因素和利用大脑区域相互连接而实施新的和现成的处罚.
- 实施快速,融合的优化策略,以解决计算GPI的计算负担.
主要成果:
- 与最先进的方法相比,MT-GPIC在阿尔茨海默氏症神经成像倡议数据集上表现出卓越的性能.
- 该方法实现了更高的相关系数和改善了AD相关分析中的分类准确性.
- MT-GPIC成功地在高维的奥米克数据中确定了可解释的,与表型相关的GPI和相关性模式.
结论:
- 开发的MT-GPIC方法有效地解开了AD研究中的基因型-蛋白相互作用和相关性模式.
- 研究结果表明,非添加性遗传和蛋白质效应在AD病原和成像表型中起着至关重要的作用.
- 这种方法提供了更高的诊断准确性,并为阿尔茨海默病的潜在机制提供了宝贵的见解.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35


